Itraconazol Slavia

Itraconazole, the active ingredient in Itraconazol Slavia, is an azole antifungal presented as an oral formulation for systemic use. It treats a range of fungal infections, including skin, nail, and systemic mycoses, in adult patients as prescribed by a healthcare professional.

GNH USA supplies Itraconazol Slavia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Itraconazole is an azole antifungal that interferes with fungal cell membrane synthesis, making it effective for several mycotic conditions. - Dermatophytosis: resolves skin infections caused by dermatophyte fungi. - Onychomycosis: clears fungal nail infections resistant to topical therapy. - Blastomycosis: treats systemic infection caused by Blastomyces dermatitidis. - Histoplasmosis: manages disseminated disease from Histoplasma capsulatum. - Aspergillosis: controls invasive disease due to Aspergillus species. - Candidiasis: combats systemic or mucosal Candida infections.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Diarrhea: loose stools occurring during therapy. - Elevated liver enzymes: mild increases detected in laboratory tests.

Serious or Rare Side Effects: - Hepatotoxicity: potential liver injury requiring monitoring. - Congestive heart failure: rare fluid retention and cardiac decompensation. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Safety considerations should be reviewed before initiating therapy. - Liver monitoring: obtain baseline hepatic function tests and repeat periodically. - Drug‑induced heart failure: assess cardiac status in patients with pre‑existing heart disease. - Pregnancy risk: avoid use unless benefits outweigh potential fetal risks. - Concomitant medications: review for agents that affect CYP3A4 metabolism. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Itraconazole has a notable interaction profile that requires careful management.

Major Interactions (Avoid): - Rifampin: strong inducer of CYP3A4, markedly reduces itraconazole exposure. - St. John’s wort: herbal CYP3A4 inducer that can compromise efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: may increase anticoagulant effect, monitor INR. - Statins (e.g., simvastatin): risk of elevated plasma levels, consider dose adjustment. - Proton pump inhibitors: may decrease absorption, assess therapeutic response.